Skip to main content Accessibility help

Visual hallucinations in the elderly: a case series and discussion of aetiology and treatment

  • C. Concannon (a1), P. Reynolds (a2) and A. M. Meaney (a2)



Visual hallucinations are a common phenomenon, among the older adult population. They can be functional or organic in aetiology. However, new onset visual hallucinations in this population are strongly suggestive of organic brain disease. Visual impairment, cerebrovascular disease and Parkinson’s disease are three causes of visual hallucinations, considered in this case series. The evidence in the literature, for the treatment of these conditions is scant at best. There is a paucity of randomised controlled trials available concerning possible therapeutic options.


We describe three case reports of visual hallucinations due to diverse underlying aetiologies. We then discuss the aetiologies of visual hallucinations in general and then in these particular cases and finally include results of a literature search examining the available evidence for any therapeutic options proposed.


Our three cases have different, underlying aetiologies. One case is of Charles Bonnet syndrome. The next is of visual hallucinations associated with vascular dementia. The final case is of visual hallucinations associated with Parkinson’s disease. The first two cases are of particular interest due to the efficacy of Amisulpride in both clinical scenarios.


Visual hallucinations are a common phenomenon in the elderly population

They can be due to a myriad of underlying causes. There are a number of neurochemical factors and neuroanatomical structures implicated. The evidence for psychopharmacological interventions is scanty. Randomised controlled trials are lacking in the area. An interesting finding in this case series, was of the clinical utility of Amisulpiride. Given this agent’s unique psychopharmacological profile it is possible that it may be efficacious in other cases of visual hallucinations associated with particular neurochemical factors.


Corresponding author

*Address for correspondence: Dr C. Concannon, St. Michael’s Unit, Mercy University Hospital, Cork, Ireland. (Email:


Hide All
Aarsland, D, Ballard, C, Rongve, A, Broadstock, M, Svenningsson, P (2012). Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Current Neurology Neuroscience Reports 12, 492501.
Bergman, J, Lerner, V (2002). Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clinical Neuropharmacology 25, 107110.
Bhatia, MS, Srivastava, S, Jhanjee, A (2012). Amisulpiride in Charles Bonnet syndrome. Journal of Neuropsychiatry and Clinical Neurosciences 24, 130133.
Boecker, H, Ceballos-Baumann, AO, Volk, D (2007). Metabolic alterations in patients with Parkinson’s disease and visual hallucinations. Archives of Neurology 64, 984988.
Bullock, R, Cameron, A (2002). Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Current Medical Research and Opinion 18, 258264.
Burke, W (2002). The neural basis of Charles Bonnet hallucinations: a hypothesis. Journal of Neurology, Neuroscience and Psychiatry 73, 535541.
Burn, D, Emre, M, McKeith, I (2006). Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Movement Disorders 21, 18991907.
Chen, J-H, Tzeng, N-S (2010). Successful treatment with amisulpiride for poststroke psychosis. Journal of Neuropsychiatry and Clinical Neurosciences 22, 210222:352.
Collerton, D, Dudley, R (2004). A cognitive behavioural framework for the treatment of distressing visual hallucinations in older people. Behavioral and Cognitive Psychotherapy 32, 443455.
Collerton, D, Dudley, R, Mosimann, UP (2011). Working psychologically with hallucinations in later life. PSIGE Newsletter 117, 1925.
Collerton, D, Perry, E, Mc Keith, I (2005). Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behavioral and Brain Sciences 28, 737757, Discussion 757–794.
Diederich, NJ, Pieri, V, Goetz, CG (2003). Coping strategies for visual hallucinations in Parkinson’s disease. Movement Disorders 18, 831832.
Ffytche, DH, Howard, RJ, Brammer, MJ, David, A, Woodruff, P, Williams, S (1998). The anatomy of conscious vision: an fMRI study of visual hallucinations. Nature Neuroscience 1, 738742.
Goetz, CG, Stebbins, GT (1995). Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45, 669671.
Gorgens, K, Liedtke, M (1998). Charles Bonnet syndrome. Psychiatric Praxis 25, 8586.
Harding, AJ, Halliday, GM (2001). Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathologica (Berlin) 102, 355363.
Hori, H, Terao, T, Shiraishi, Y, Nakamura, J (2000). Treatment of Charles Bonnet Syndrome with Valproate. International Clinical Psychopharmacology 15(2).
Khan, JC, Shahid, H, Thurlby, DA, Yates, JR, Moore, AT (2008). Charles bonnet syndrome in age-related macular degeneration: the nature and frequency of images in subjects with end stage disease. Ophthalmic Epidemiology 15, 202208.
Lang, UE, Stogowski, D, Schulze, D, Domula, M, Schmidt, E, Gallinat, J, Tugtekin, SM, Felber, W (2007). Charles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. Journal of Psychopharmacology 21, 553555.
Leucht, S, Pitschel-Waltz, G, Engel, R, Kissling, W (2002). Amisulpride, an unusual “atypical” antipsychotic – a meta analysis of randomised controlled trials. American Journal of Psychiatry 159, 180190.
Lippa, CF, Duda, JE, Grossman, M, Hurtig, HI, Aarsland, D, Boeve, BF, Brooks, DJ, Dickson, DW, Dubois, B, Emre, M, Fahn, S, Farmer, JM, Galasko, D, Galvin, JE, Goetz, CG, Growdon, JH, Gwinn-Hardy, KA, Hardy, J, Heutink, P, Iwatsubo, T, Kosaka, K, Lee, VM, Leverenz, JB, Masliah, E, McKeith, IG, Nussbaum, RL, Olanow, CW, Ravina, BM, Singleton, AB, Tanner, CM, Trojanowski, JQ, Wszolek, ZK, DLB/PDD Working group (2007). DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812819.
Maeda, K, Shirayama, Y, Nukina, S, Yoshioka, S, Karahara, R (2003). Charles Bonnet syndrome with visual hallucinations of childhood experiences: successful treatment of one patient with risperidone. Journal of Clinical Psychiatry 64, 11311132.
Manford, M, Andermann, F (1998). Review article complex visual hallucinations. Clinical and neurobiological insights. Brain 121, 18191840.
Matsui, H, Nishinaka, K, Oda, M, Hara, N (2006a). Hypoperfusion of the visual pathway in PDs with visual hallucinations. Movement Disorders 21, 21402144.
Matsui, H, Nishinaka, K, Oda, M, Hara, N (2006b). Hypoperfusion of the visual pathway in PDs with visual hallucinations. Movement Disorders 21, 21652169.
McKeith, I, Del Ser, T, Spano, P, Emre, M, Wesnes, K, Anand, R, Cicin-Salin, A, Ferrara, R, Spiegel, R (2000). Efficacy of rivastigmine in dementia with Lewy bodies – a randomised, double blind, placebo controlled international study. Lancet 356, 20312036.
Menon, GJ, Rahman, I, Menon, SJ, Dutton, GN (2003). Complex visual hallucinations in the visually impaired: the Charles Bonnet syndrome. Survey of Ophthalmology 48, 5872.
Mosimann, UP, Collerton, D (2010). Hallucinations in the context of dementing illnesses. In Hallucinations: A Guide to Treatment and Management (ed. F Laroi and A Aleman), pp. 323350. Oxford University Press: Oxford, UK.
National Institute for Clinical Excellence (NICE) (2010). Delirium: Diagnosis, Prevention and Management. Clinical Guideline 103. National Clinical Guideline Centre: London, UK.
Paulig, M, Mentrup, H (2001). Charles Bonnet syndrome: complete remission of complex visual hallucinations treated by gabapentin. Journal of Neurology, Neurosurgery and Psychiatry 70, 813814.
Perry, EK, Kilford, L, Lees, AJ, Burn, DJ, Perry, RH (2003). Increased Alzeimer pathology in Parkinson’s disease related to antimuscarinic drugs. Annals of Neurology 54, 235238.
Qu, Y, Eysel, UT, Vandesande, F, Arckens, L (2000). Effect of partial sensory deprivation on monoaminergic neuromodulators in striate cortex of adult cat. Neuroscience 101, 863868.
Ramirez-Ruiz, B, Junque, C, Marti, M-J, Valldeoriola, F, Tolossa, E (2007). Cognitive changes in Parkinson’s disease patients with visual hallucinations. Dementia and Geriatric Cognitive Disorders 23, 281288.
Ranen, NG, Pasternak, RE, Rovner, BW (1999). Cisapride in the treatment of visual hallucinations caused by vision loss – the CBS syndrome. American Journal of Geriatric Psychiatry 7, 264266.
Rushmore, RJ, Payne, BR, Lombar, SG (2005). Functional impact of the primary visual cortex deprivation in subcortical target structures in the thalamus and the midbrain. Journal of Comparative Neurology 488, 414426.
Seeburg, DP, Liu, X, Chen, C (2004). Frequency-dependent modulation of retinogeniculate transmission by serotonin. The Journal of Neuroscience 24, 1095010962.
Skovronsky, DM, Lee, VMY, Trojanowski, JQ (2006). Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic complications. Annual Review of Pathology 1, 151170.
Stebbins, GT, Goetz, CG, Carillo, MC (2004). Altered cortical visual processing in Parkinson’s disease with hallucinations: an fMRI study. Neurology 63, 14091416.
Ukai, S, Yakamoto, M, Tanaka, M, Takeda, M (2004). Treatment of typical Charles Bonnet syndrome with donepezil. International Clinical Psychopharmacology 19, 355357.
Valencia, C, Franco, JG (2008). Charles Bonnet syndrome: report of one case managed with haloperidol. Revista médica de Chile 136, 347350.
Victor, M, Adams, RD (1952). The effect of alcohol on the nervous system. In Metabolic and Toxic Disease of the Nervous System (ed. HH Merritt and CC Hare), pp. 526573. Williams and Wilkins: Baltimore.
Webster, R, Holroyd, S (2000). Prevalence of psychotic symptoms in delirium Psychosomatics 41, 519522.
West, LJ (1962). A general theory of hallucinations and dreams. chapter 26. In Hallucinations (ed. Grune and Stratton), pp. 273291. Grune & Stratton: New York.
Williams-Gray, CH, Foltynie, TH, Lewis, SJG, Barker, RA (2006). Cognitive deficits and psychosis in Parkinson’s disease: a review of pathophysiology and therapeutic options. CNS Drugs 20, 477505.
Wolters, ACH (2006). Parkinson’s disease-related psychosis: pathophysiology with therapeutical strategies. Journal of Neural Transmission 71 (Suppl.): 3137.


Visual hallucinations in the elderly: a case series and discussion of aetiology and treatment

  • C. Concannon (a1), P. Reynolds (a2) and A. M. Meaney (a2)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed